Press Center

Here you will find current press releases and press kits of tesa Labtec GmbH.

  1. FDA Key Visual Black.jpg 02/26/16

    tesa Labtec announces successful completion of FDA Pre-Approval Inspections

    The German patch and oral thin film maker announces the completion of a Pre-Approval Inspection (PAI) by the US Food and Drug Administration (FDA) in February 2016.

  2. US office 05/12/15

    tesa Labtec opens US office

    The German patch and oral-film maker announces the opening of its own business development office in the US, targeting the biggest pharmaceutical market globally while improving customer focus.

  3. New R&D Pilot Production Facility 07/28/14

    New R&D Pilot Production Facility

    tesa Labtec Opens LabFactory

  4. Strong and knowledgeable production team 05/25/11

    Labtec opens Europe’s most modern GMP manufacturing facility for transdermal patches and oral films

    Labtec GmbH has become a fully authorized manufacturer for transdermal drug delivery systems and oral dispersible films with its proprietary RapidFilm® technology.

  5. Sufentanil 11/01/10

    Sufentanil enters Phase II clinical development

    Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch.

  6. tesa_Anlage_034.jpg 06/21/10

    Labtec and GSK finalize license agreement for an innovative topical patch to treat cold sores

    GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec.

  7. Labtec 03/23/10

    European Approval of Ondansetron Rapidfilm®

    APR Applied Pharma Research s.a. and Labtec GmbH announce the European Approval of Ondansetron Rapidfilm®, co-developed in partnership with MonoSol Rx and licensed to BioAlliance Pharma SA for EU countries.

  8. tesa Labtec TTS 10/06/09

    tesa focuses on Growth Markets in the Healthcare Sector

    Active ingredients pass through the skin or dissolve on the tongue

  9. Labtec 01/29/08

    Successful completion of the pilot bioequivalence study of Donepezil Rapidfilm®

    APR Applied Pharma Research s.a. and Labtec GmbH announce the successful completion of the pilot bioequivalence study of their Donepezil Rapidfilm® further confirming the validity and adaptability of this innovative proprietary technology.